Efficacy of hypofractionated radiotherapy for nasal tumours in 38 dogs (2005–2008)

Fujiwara, Ayako; Kobayashi, Tetsuya; Kazato, Yukari; Yayoshi, Naoko; Fujita, Michio

doi:10.1111/jsap.12024

Cited by 17 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the proximity of the eyes to the nasal cavity, ocular complications are frequently described and, in humans, doses above 10–18 Gy have been reported to be potentially cataractogenic . Overall, in the present study, late side effects were lower than those described in similar reports . Unilateral cataract was observed in two patients 12 and 14 months after the end of RT.…”

Section: Discussioncontrasting

confidence: 65%

“…Late side effects can occur from months to years postradiation. It is generally accepted that the use of a hypofractionated regimen can increase the incidence of late complications as compared to a multifractionated regimen . Due to the proximity of the eyes to the nasal cavity, ocular complications are frequently described and, in humans, doses above 10–18 Gy have been reported to be potentially cataractogenic .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Combination of Radiation Therapy and Firocoxib for the Treatment of Canine Nasal Carcinoma

Cancedda

Sabattini

Bettini

et al. 2015

Vet Radiology Ultrasound

View full text Add to dashboard Cite

Carcinomas represent two-thirds of canine nasosinal neoplasms. Although radiation therapy (RT) is the standard of care, the incidence of local recurrence following treatment is high. Cyclooxygenase-isoform-2 (COX-2) is expressed in 71-95% of canine nasal carcinomas and has been implicated in tumor growth and angiogenesis. Accordingly, COX-2 inhibition seems rational to improve outcome. Dogs with histologically confirmed, previously untreated nasal carcinomas were randomized to receive the combination of a selective COX-2 inhibitor (firocoxib) and palliative RT (Group 1) or RT and placebo (Group 2). Patients were regularly monitored with blood tests, urinalysis, and computed tomography. Pet owners were asked to complete monthly a quality-of-life questionnaire. Twenty-four dogs were prospectively enrolled. According to Adams modified system, there were five stage 1, five stage 2, three stage 3, and 11 stage 4 tumors. Two dogs had metastases to regional lymph nodes. Median progression-free interval and overall survival were 228 and 335 days in Group 1 (n = 12) and 234 and 244 days in Group 2 (n = 12). These differences were not statistically significant. The involvement of regional lymph nodes was significantly associated with progression-free interval and overall survival (P = 0.004). Quality of life was significantly improved in Group 1 (P = 0.008). In particular, a significant difference was observed for activity and appetite. Although not providing a significant enhancement of progression-free interval and overall survival, firocoxib in combination with RT is safe and improved life quality in dogs with nasal carcinomas.

show abstract

Section: Discussioncontrasting

confidence: 65%

Section: Discussionmentioning

confidence: 99%

Combination of Radiation Therapy and Firocoxib for the Treatment of Canine Nasal Carcinoma

Cancedda

Sabattini

Bettini

et al. 2015

Vet Radiology Ultrasound

View full text Add to dashboard Cite

show abstract

“…[1][2][3] While radiation therapy can be used to treat a variety of tumor types, nasal tumors are a classic example in which radiation therapy alone is considered standard of care treatment, although optimal protocols remain unclear. [4][5][6][7][8][9][10][11][12][13][14] Prospective, randomized clinical trials are needed to determine the optimal radiation technique and fractionation that provide the most effective means of long-term local control, as is done in human medicine. It is vital that standardized criteria exist in which to assess response to therapy, thereby facilitating determination of the best treatment protocols.…”

mentioning

confidence: 99%

Volumetric tumor response assessment is inefficient without overt clinical benefit compared to conventional, manual veterinary response assessment in canine nasal tumors

Nell

Ober

Forrest

et al. 2020

Vet Radiology Ultrasound

View full text Add to dashboard Cite

Accurate assessment of tumor response to therapy is critical in guiding management of veterinary oncology patients and is most commonly performed using response evaluation criteria in solid tumors criteria. This process can be time consuming and have high intra‐ and interobserver variability. The primary aim of this serial measurements, secondary analysis study was to compare manual linear tumor response assessment to semi‐automated, contoured response assessment in canine nasal tumors. The secondary objective was to determine if tumor measurements or clinical characteristics, such as stage, would correlate to progression‐free interval. Three investigators evaluated paired CT scans of skulls of 22 dogs with nasal tumors obtained prior to and following radiation therapy. The automatically generated tumor volumes were not useful for canine nasal tumors in this study, characterized by poor intraobserver agreement between automatically generated contours and hand‐adjusted contours. The radiologist's manual linear method of determining response evaluation criteria in solid tumors categorization and tumor volume is significantly faster (P < .0001) but significantly underestimates nasal tumor volume (P < .05) when compared to a contour‐based method. Interobserver agreement was greater for volume determination using the contour‐based method when compared to response evaluation criteria in solid tumors categorization utilizing the same method. However, response evaluation criteria in solid tumors categorization and percentage volume change were strongly correlated, providing validity to response evaluation criteria in solid tumors as a rapid method of tumor response assessment for canine nasal tumors. No clinical characteristics or tumor measurements were significantly associated with progression‐free interval.

show abstract

“…Canine intranasal melanoma has been successfully treated with surgery and radiotherapy once before (Hicks & Fidel 2006). Radiotherapy is a common primary treatment for intranasal neoplasia, producing clinical benefit in over 80% of dogs and a median survival time (MST) of over 500 days (Fujiwara et al 2013). Radiotherapy is also effective in controlling oral melanomas, with an overall response rate of 83% (Bateman et al 1994;Proulx et al 2003) and a MST of 80-758 days, depending on factors such as tumour stage, sub-location in the oral cavity and the degree of osteolysis (Proulx et al 2003;Freeman et al 2003;Kawabe et al 2015).…”

Section: Discussionmentioning

confidence: 99%

Intranasal melanoma treated with radiation therapy in three dogs

Davies

Spencer

Néčová³

et al. 2017

Veterinary Quarterly

View full text Add to dashboard Cite

Three dogs were investigated for chronic unilateral nasal discharge. In all cases CT imaging showed an intranasal mass causing turbinate lysis and no evidence of metastasis. Cytology in cases 1 (a 14-year-old neutered male crossbreed dog) and 2 (a five-year-old neutered male German Shepherd dog) demonstrated a pleomorphic cell population with variable intracellular pigment suspicious of melanocytic neoplasia. Histopathology with immunohistochemistry (Melan-A and vimentin, plus PNL-2 in one case) confirmed the diagnosis of melanoma in all dogs. All dogs were treated with megavoltage radiotherapy using linear accelerators. Cases 1 and 3 (a 9-year-old neutered female beagle dog) received a hypofractionated (4x8 Gy) protocol and case 2 received a definitive (12x4 Gy) protocol. Complete remission was demonstrated on repeat CT scan 5 months after diagnosis in case 1 and 7 months in case 2. Stable disease was documented on CT at four months for case 3, however, clinical signs in this dog remained controlled for 10 months in total. Case 1 died of unrelated causes 5 months after diagnosis, case 2 was euthanased due to the development of seizures 13 months after diagnosis, and case 3 was lost to follow-up 12 months after diagnosis. Melanoma should be considered as a rare differential diagnosis for primary nasal neoplasia in the dog and radiation therapy can be used as effective local therapy.

show abstract

Efficacy of hypofractionated radiotherapy for nasal tumours in 38 dogs (2005–2008)

Abstract: These results suggest that hypofractionated radiotherapy could be a viable option for the treatment of nasal tumours in dogs that are not candidates for conventional multi-fractionated radiotherapy.

Cited by 17 publications

References 19 publications

Combination of Radiation Therapy and Firocoxib for the Treatment of Canine Nasal Carcinoma

Combination of Radiation Therapy and Firocoxib for the Treatment of Canine Nasal Carcinoma

Volumetric tumor response assessment is inefficient without overt clinical benefit compared to conventional, manual veterinary response assessment in canine nasal tumors

Intranasal melanoma treated with radiation therapy in three dogs

Contact Info

Product

Resources

About